Carvedilol/lisinopril

Drug Profile

Carvedilol/lisinopril

Alternative Names: Coreg CR + ACEi; COREG CR and lisinopril (FDC); COREG CR/Zestril; Lisinopril/carvedilol; Zestril/COREG CR

Latest Information Update: 10 Jan 2017

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Class Antihypertensives; Carbazoles; Heart failure therapies; Propanolamines
  • Mechanism of Action ACE inhibitors; Alpha 1 adrenergic receptor antagonists; Alpha beta adrenergic receptor antagonists; Beta-adrenergic receptor antagonists; Calcium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Hypertension

Most Recent Events

  • 30 Sep 2007 Phase-III clinical trials in Hypertension (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top